Drug Trial Radar · NCT03697109
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
Last checked: Nov 19, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
152
Actual
Start
Nov 15, 2018
Primary completion
Apr 8, 2024
Study completion Apr 15, 2024
Sponsor
- Lead sponsor
- Corcept TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 5, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes mellitus/impaired glucose tolerance (DM/IGT) and/or uncontrolled hypertension (HTN).
Conditions
- Cushing Syndrome
Interventions
RelacorilantDrug
Relacorilant is supplied as 100 mg capsules for oral dosing.
PlaceboOther
Placebo matched to study drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients With Loss of Response With Respect to Hypertension During the RW Phase.Time frame: Week 22 (end of OL Phase) and Week 36 (Week 12 of RW Phase)
- Number of Patients With 1 or More Treatment-emergent Adverse Events (TEAEs) as Graded by CTCAE v5.0.Time frame: OL Phase: Up to 22 weeks; RW Phase: up to 18 weeks after completion of the OL Phase
Locations
64 sites in 11 countries. Site status is shown where the registry gives one.
Site 21
Phoenix, Arizona
Site 36
Los Angeles, California
Site 68
Torrance, California
Site 10
Miami, Florida
Site 14
Atlanta, Georgia
Site 41
Chicago, Illinois
Site 7
Indianapolis, Indiana
Site 2
Metairie, Louisiana
Site 45
Baltimore, Maryland
Site 46
Boston, Massachusetts
Site 20
Ann Arbor, Michigan
Site 4
Jackson, Mississippi
Site 13
St Louis, Missouri
Site 53
Omaha, Nebraska
Site 72
Reno, Nevada
Site 8
Albany, New York
Site 6
Jamaica, New York
Site 57
New York, New York
Site 35
New York, New York
Site 39
New York, New York
Site 1
Wilmington, North Carolina
Site 17
Columbus, Ohio
Site 11
Oklahoma City, Oklahoma
Site 62
Philadelphia, Pennsylvania
Site 19
Pittsburgh, Pennsylvania
Site 71
Pittsburgh, Pennsylvania
Site 5
Summerville, South Carolina
Site 51
Dallas, Texas
Site 3
El Paso, Texas
Site 65
Houston, Texas
Site 56
Shavano Park, Texas
Site 31
Everett, Washington
Site 47
Vienna, Austria
Site 27
Sofia, Bulgaria
Site 58
Montreal, Canada
Site 70
Halifax, Nova Scotia, Canada
Site 54
München, Germany
Site 49
Würzburg, Germany
Site 30
Jerusalem, Israel
Site 29
Kfar Saba, Israel
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.